STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
|
|
|
- Nickolas Hutchinson
- 5 years ago
- Views:
Transcription
1 STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators
2 Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity: Background native LDL carrier of Lp-PLA 2 Lp-PLA 2 Leukocyte Lumen Atheroma Intima Lp-PLA 2 Sustained Inflammation Necrotic Core Expansion Oxidized LDL substrate for Lp-PLA 2 Macphee, Biochem J 1999; Zalewski and Macphee, ATVB 2005; Shi Atherosclerosis 2007; Kolodgie, ATVB
3 Contrasting histopathological characteristics of a stable versus a vulnerable or ruptured plaque Corson et al. Am J Card 2008;101(Suppl):41F-50F Thick Fibrous Cap Thin Fibrous Cap Modest Lipid Pool Large Lipid Pool Lumen Lumen Lp-PLA 2 Lp-PLA 2 Stable Plaque Low Lp-PLA 2 content (dark staining) May have significant stenosis Thick fibrous cap / high collagen content Modest lipid pool Few inflammatory cells Vulnerable or ruptured Plaque High Lp-PLA 2 content (dark staining) May have minimal stenosis Thin fibrous cap / low collagen content Large lipid pool Many inflammatory cells
4 Lp-PLA 2 and CHD risk: The Lp-PLA 2 Studies Collaboration; compared with conventional risk factors 79,036 participants from 32 prospective studies RR (95% CI) per 1 - SD higher Lp-PLA 2 activity 1.11 ( ) Systolic blood pressure Smoking status * n - HDL cholesterol HDL cholesterol 1.10 ( ) 1.34 ( ) 1.10 ( ) 1.15 ( ) Adjusted for non-lipid and lipid conventional risk factors LSC Lancet 2010; 375:1536 4
5 STABILITY: Background Association studies EPIDEMIOLOGY Higher Lp-PLA 2 levels predict CV events GENETICS Deficiency in Lp-PLA 2 due to null allele results in decreased CHD PATHOLOGY Up-regulation of Lp- PLA 2 in vulnerable plaques Darapladib is a selective oral inhibitor that decreases Lp-PLA 2 by 60% Intervention with darapladib PRECLINICAL Reduces Lp-PLA 2 in plaque and necrotic core area (pig) HUMAN ATHEROMA Reduces carotid plaque Lp-PLA 2 activity CORONARY IMAGING IBIS-2 Halts progression of coronary artery necrotic plaque core volume
6 STABILITY Trial Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Patients with chronic CHD (prior MI >1 mth, prior coronary revascularization, multivessel CAD) Enrichment criteria: 60 years of age, diabetes mellitus, low HDL, current smoking, significant renal dysfunction, polyvascular disease 15,828 patients randomized Darapladib 160mg Placebo Optimized guideline-mandated treatment median follow-up 3.7 years, 1588 events Primary endpoint: composite of CV death, MI, stroke Secondary endpoints: major coronary events, total coronary events 6
7 Key Exclusion Criteria Planned coronary revascularization Current liver disease or severe renal impairment Current severe heart failure Poorly controlled hypertension Severe asthma that is poorly controlled History of anaphylaxis, anaphylactoid reactions, or severe allergic responses Concomitant cytochrome P-450 inhibitor use Lp-PLA 2 activity 20.0 nmol/min/ml 7
8 Recruitment into STABILITY Trial (N=15,828) rth America (25%) USA 3102 Canada 780 Mexico 141 Western Europe (22%) Belgium 202 Denmark 102 France 250 Greece 187 Germany 1089 Italy 256 Netherlands 444 rway 113 Spain 474 Sweden 299 UK 184 Eastern Europe (22%) Bulgaria 222 Cz Republic 774 Estonia 77 Hungary 410 Poland 510 Romania 411 Russia 654 Slovakia 120 Ukraine 353 E & SE Asia China 369 Korea 503 Hong Kong 117 Taiwan 200 Japan 318 South America India 398 Pakistan 250 Thailand 207 Philippines 219 Australia 306 New Zealand 202 Argentina 542 Brazil 384 Chile 195 Peru 78 South Africa 386 Asia-Pacific/Latina (31%) 8
9 Demographics Placebo (N=7904) Darapladib (N=7924) Age: Median in years <65 years (%) 49% 48% years (%) 37% 38% >=75 years (%) 14% 14% Female (%) 19% 18% Race or Ethnic Group (%) White 78% 79% Black 2% 2% Central/South/South East Asian 8% 7% East Asian/Japanese 10% 10% Other 2% 2% 9
10 Chronic Coronary Heart Disease Qualifying Diagnosis Placebo (N=7904) Darapladib (N=7924) Prior MI 59% 59% Coronary revascularization 75% 75% PCI 50% 50% CABG 33% 33% Multi-vessel CAD 15% 15% 10
11 Enrichment Criteria Placebo (N=7904) Darapladib (N=7924) Age 60 years 73% 73% Diabetes req. pharmacotherapy 34% 34% HDL < 40 mg/dl (1.03 mmol/l) 35% 33% Current smoker or former smoker within 3 months ( 5 cigs/day) Significant renal dysfunction (egfr 30 to 59 ml/min/1.73 m 2 or urine ACR 3 mg albumin/g creatinine) Polyvascular disease (cerebrovascular disease or peripheral arterial disease) 21% 20% 30% 30% 15% 15% 11
12 Baseline LDL LDL-C (mg/dl) Placebo (N=7904) Darapladib (N=7924) Median (Interquartile range) 80 (63 101) 80 (63 101) <70 (<1.8mmol/L) 36% 35% ( mmol/l) 38% 39% 100 ( 2.6 mmol/l) 26% 26% 12
13 Concomitant Medication Usage Time Point Placebo (N=7904) Darapladib (N=7924) Aspirin Baseline Study end 93% 91% 92% 90% Statins Baseline Study end 97% 96% 97% 96% Beta-Blockers Baseline Study end 79% 79% 79% 78% P2Y12 Inhibitors Baseline Study end 34% 27% 34% 27% ACE inhibitor Baseline Study end 56% 54% 57% 54% Angiotensin II receptor blocker Baseline Study end 23% 27% 22% 26% 13
14 Standard of Care Measures LDL-Cholesterol (mg/dl) Time Point Placebo (N=7890) Darapladib (N=7912) Median (Interquartile range) Baseline Study end 80 (63 101) 79 (62 100) 80 (63 101) 78 (61 99) Blood Pressure (mmhg) Mean Baseline Study end 132/79 mmhg 131/77 mmhg 132/79 mmhg 132/77 mmhg 14
15 Subject Status Overview Placebo (N=7904) Darapladib (N=7924) IP Discontinuation 26.8% 32.7% Study Withdrawal 273 (3.5%) 278 (3.5%) Complete CV Endpoint Follow-up 7628 (96.5%) 7641 (96.4%) Complete Vital Status Follow-up 7845 (99.3%) 7877 (99.4%) Median follow-up time was 3.7 years for both treatment groups Adherence (> 80%) was 91.3% for placebo and 89.3% for darapladib 15
16 Primary Endpoint: Time to First Occurrence CV Death, MI, Stroke HR (95% CI)= 0.94 (0.85, 1.03) P-value = Placebo events = 819 Darapladib 160mg events =
17 Baseline Status Baseline Status Baseline Status Multivessel CHD: Age 60: Darapladib 1.03 (0.82, 1.29) 147 (12.3%) Subgroup Analyses for CV Death, 0.91 (0.80, 1.03) MI, Stroke (9.1%) Diabetes req. pharmacotherapy: Gender: Male Female HDL-C level <40 mg/dl: Race collapsed: White n-white Favors Smoker: Prior myocardial infarction: Darapladib Age 60: Renal dysfunction: Prior coronary revascularization: Gender: Male Polyvascular Multivessel Disease: CHD: Female Race collapsed: White Pre-Study Diabetes CHD req. Event: pharmacotherapy: n-white Recent Prior myocardial infarction: Remote Statin HDL-C use: level <40 mg/dl: Prior coronary revascularization: Smoker: egfr: <60 ml/min/1.73m 2 Multivessel CHD: 60 ml/min/1.73m 2 Renal dysfunction: Diabetes Baseline req. LDL: pharmacotherapy: <70 mg/dl 70 - <100 mg/dl Polyvascular Disease: 100 mg/dl HDL-C level <40 mg/dl: hs C-reactive protein: <1.0 mg/l Pre-Study CHD Event: Smoker: mg/l Recent >3.0 mg/l Remote Renal Region: Statin dysfunction: use: rth America Eastern Europe Western Europe Polyvascular egfr: Disease: <60 South ml/min/1.73m America 2 60Asia/Pacific ml/min/1.73m 2 Placebo Favors Placebo HR (95% CI) P-value Placebo Darapladib 0.92 (0.82, 1.03) (10.0%) 620 (9.2%) 0.98 (0.80, 1.20) (8.8%) 149 (12.4%) 182 (8.6% 0.92 (0.82, 1.03) 628 (10.9%) 587 (10.1% 435 (8.3%) (0.85, (0.83, 1.14) 1.03) (12.7%) 670 (10.5%) 334 (12.5%) 624 (9.7% 1.01 (0.80, 1.26) 149 (9.9%) 145 (9.9% 0.94 (0.83, 1.07) (9.8%) 486 (9.2%) (0.80, (0.80, 1.10) 1.00) (11.3%) 675 (10.9%) 281 (10.6%) 610 (9.8% 1.13 (0.90, 1.41) Interaction Number 144 (8.3%) of Events 159 (%) (9.4% 0.99 (0.89, 1.11) (10.0%) 625 (9.9%) 0.77 HR 0.87 (0.62, (95%(0.74, CI) 0.96) 1.03) P-value Placebo (11.6%) 314 (9.6%) 140 Darapladib 274 (8.9%) (8.4% (0.80, (0.86, 1.20) 1.10) (8.8%) (10.9%) (8.6%) (10.6% 0.87 (0.77, 0.99) (8.7%) 420 (7.6%) (0.89, (0.82, (0.80, 1.19) 1.03) 1.14) (14.2%) 244 (10.9%) (12.2%) (14.5%) 229 (10.1%) (11.6% (0.83, (0.83, 1.03) 1.05) (10.5%) (9.7%) (9.7%) (9.1% (0.83, (0.80, 1.04) 1.26) (9.3%) (9.9%) (8.7%) 0.92 (0.82, 1.03) (10.0%) 620 (9.9%) (9.2% (0.78, (0.80, (0.82, 1.17) 1.00) 1.29) 193 (16.3%) (10.9%) (12.3%) 185 (15.6%) (9.8%) (12.4% (0.72, (0.90, (0.80, 1.08) 1.41) 1.03) (10.2%) 477 (8.3%) (9.1%) (9.1%) (9.4%) (8.3% (0.86, (0.74, (0.85, 1.07) 1.03) 1.14) (10.4%) 342 (9.6%) (12.7%) (9.9%) (8.4%) (12.5% (0.46, (0.86, (0.83, 1.38) 1.10) 1.07) (13.0%) 502 (10.9%) (9.8%) (10.7%) 486 (10.6%) (9.2% (0.85, (0.80, (0.80, 1.04) 1.14) 1.10) (10.3%) 316 (12.2%) (11.3%) (11.6%) (9.7%) (10.6% (0.83, (0.89, 1.05) 1.11) (9.7%) (10.0%) (9.1%) (9.9% 0.90 (0.73, 1.10) (17.0%) (0.86, (0.82, (0.62, 1.07) 1.03) 0.96) (10.0%) (11.6%) 165 (15.2%) (9.2%) (8.9%) (9.2%) (8.9% (0.82, (0.77, 1.29) 0.99) (12.3%) (8.7%) (12.4%) (7.6% (0.87, (0.80, (0.89, 1.23) 1.03) 1.19) (8.7%) (9.1%) (14.2%) (9.0%) (8.3%) (14.5% (0.81, (0.85, 1.12) 1.14) (12.7%) (9.6%) (12.5%) (9.1%) (0.71, (0.83, 1.00) 1.04) (13.7%) 626 (9.3%) 240 (11.6%) 584 (8.7% (0.83, (0.78, 1.07) 1.17) (9.8%) (16.3%) (9.2%) (15.6% (0.83, (0.80, 1.22) 1.10) (11.3%) (7.6%) (10.6%) (7.6%) (0.75, (0.72, (0.89, 1.05) 1.08) ) (10.8%) 194 (10.2%) (10.0%) (9.7%) (9.1% (9.9%) (0.75, (0.86, (0.62, 1.08) 1.07) 0.96) (13.6%) 623 (10.4%) (11.6%) (12.2%) 596 (9.9% (8.9%) (0.74, (0.77, (0.46, 1.09) 0.99) 1.38) (10.6%) 29 (8.7%) (13.0%) (9.5%) 22 (7.6%) (10.7% (0.77, (0.89, (0.85, 1.15) 1.19) 1.04) (10.9%) 790 (14.2%) (10.3%) (10.2%) 747 (14.5%) (9.7% 0.89 (0.73, 1.09) 207 (10.5%) 187 (9.3%) (0.74, (0.83, (0.73, 1.41) 1.04) 1.10) (12.2%) 191 (9.3%) (17.0%) (12.3%) 165 (8.7%) (15.2% (0.81, (0.78, (0.86, 1.31) 1.17) 1.07) (16.3%) (8.6%) (9.2%) (15.6%) (8.9%) (8.9% Pre-Study Baseline CHD LDL: Event: Recent <70 mg/dl (0.72, (0.87, 1.08) 1.23) (10.2%) (8.7%) (9.1%) (9.0% 70 - <100 Remote mg/dl (0.86, (0.81, 1.07) 1.12) (10.4%) (9.6%) (9.9%) (9.1% 100 mg/dl Hazard Ratio 0.84 (0.71, 1.00) 281 (13.7%) 240 (11.6% Statin use: 0.79 (0.46, 1.38) (13.0%) 22 (10.7%) hs C-reactive protein: <1.0 mg/l (0.85, (0.83, 1.04) 1.22) (10.3%) (7.6%) (9.7%) (7.6% mg/l 0.89 (0.75, 1.05) 283 (10.8%) 253 (9.7% egfr: <60 ml/min/1.73m >3.0 mg/l (0.73, (0.75, 1.10) 1.08) (17.0%) (13.6%) (15.2%) (12.2% Region: 60 ml/min/1.73m rth America (0.86, 1.07) 625 (9.2%) 604 (8.9%) 0.90 (0.74, 1.09) (10.6%) 190 (9.5% Baseline LDL: Eastern <70 mg/dl Europe (0.87, (0.77, 1.23) 1.15) (8.7%) (10.9%) (9.0%) (10.2%
18 Baseline Status Baseline Status Baseline Status Subgroup 0.94 Analyses for CV Death, 0.93 (0.83, (0.80, 1.07) 1.10) (9.8%) MI, Stroke 316 (11.3%) HDL-C Age level 60: <40 mg/dl: Smoker: Gender: Renal Race dysfunction: collapsed: Male Female White n-white Darapladib 18 Placebo 0.98 (0.85, HR (95% 1.14) CI) P-value 342 (12.7%) Placebo334 (12.5%) Darapladib 0.98 (0.80, 1.20) (8.8%) (9.2%) (8.6% 0.92 (0.82, 1.03) 628 (10.9%) (10.6%) (10.1% (0.89, (0.83, 1.11) 1.03) (10.0%) (10.5%) (9.9%) (9.7% (0.62, (0.80, 0.96) 1.26) (11.6%) (9.9%) (8.9%) (9.9% (0.77, (0.80, 0.99) 1.00) (8.7%) (10.9%) (7.6%) (9.8% (0.89, (0.90, 1.19) 1.41) (14.2%) (8.3%) (14.5%) (9.4% Polyvascular Prior myocardial Disease: infarction: Favors Favors (0.83, (0.74, 1.04) 1.03) (9.3%) (9.6%) (8.7%) (8.4% (0.78, (0.86, 1.17) 1.10) Interaction Number (16.3%) (10.9%) of Events (15.6%) (10.6% (%) Darapladib Placebo HR (95% CI) P-value Placebo Darapladib Prior coronary revascularization: 0.95 (0.80, 1.14) (12.2%) 229 (11.6% Age Pre-Study 60: CHD Event: Recent (0.72, (0.80, (0.83, 1.08) 1.20) 1.05) (10.2%) (8.8%) (9.7%) (9.1%) (8.6%) (9.1% Remote (0.86, (0.82, 1.07) 1.03) (10.4%) (10.9%) (10.1%) (9.9%) Multivessel CHD: 0.92 (0.82, 1.03) (10.0%) 620 (9.2% Gender: Statin use: Male (0.46, (0.83, (0.82, 1.38) 1.03) 1.29) (13.0%) (10.5%) (12.3%) (10.7%) (9.7%) (12.4% Female (0.85, (0.80, 1.04) 1.26) (10.3%) (9.9%) (9.7%) (9.9%) Diabetes req. pharmacotherapy: 0.91 (0.80, 1.03) (9.1%) 435 (8.3% Race collapsed: White <60 ml/min/1.73m egfr: (0.80, (0.73, (0.85, 1.00) 1.10) 1.14) (10.9%) (17.0%) (12.7%) (9.8%) (15.2%) (12.5% n-white 1.13 (0.90, 1.41) 144 (8.3%) 159 (9.4%) HDL-C level <40 60mg/dL: ml/min/1.73m (0.86, (0.83, 1.07) 1.07) (9.2%) (9.8%) (8.9%) (9.2% Prior myocardial infarction: (0.74, (0.80, 1.03) 1.10) (9.6%) (11.3%) (8.4%) (10.6% Baseline LDL: <70 mg/dl (0.87, (0.86, 1.23) 1.10) (10.9%) (8.7%) (10.6%) (9.0%) Smoker: 70 - <100 mg/dl 0.99 (0.81, (0.89, 1.12) 1.11) (9.6%) (10.0%) (9.1%) (9.9% Prior coronary revascularization: 100 mg/dl (0.80, (0.71, (0.62, 1.14) 1.00) 0.96) (12.2%) (13.7%) (11.6%) (11.6%) (11.6%) (8.9% 0.93 (0.83, 1.05) 575 (9.7%) 540 (9.1%) Renal dysfunction: 0.87 (0.77, 0.99) (8.7%) 420 (7.6% Multivessel hs C-reactive CHD: protein: <1.0 mg/l (0.83, (0.82, (0.89, 1.22) 1.03) 1.19) (10.0%) (7.6%) (14.2%) (7.6%) (9.2%) (14.5% mg/l (0.75, (0.82, 1.05) 1.29) (10.8%) (12.3%) (12.4%) (9.7%) Diabetes Polyvascular req. pharmacotherapy: Disease: >3.0 mg/l (0.75, (0.80, (0.83, 1.08) 1.03) 1.04) (13.6%) (9.1%) (9.3%) (12.2%) (8.3%) (8.7% Region: rth America (0.78, 1.17) 193 (16.3%) 185 (15.6% 0.90 (0.74, (0.85, 1.09) 1.14) (10.6%) (12.7%) (12.5%) (9.5%) HDL-C Pre-Study level <40 CHD mg/dl: Event: Eastern Europe Recent (0.77, (0.83, (0.72, 1.15) 1.07) 1.08) (10.9%) (9.8%) (10.2%) (10.2%) (9.2%) (9.1% Western Europe Remote (0.73, (0.80, (0.86, 1.09) 1.10) 1.07) (10.5%) (11.3%) (10.4%) (10.6%) (9.3%) (9.9% Smoker: South America 1.02 (0.74, 1.41) 73 (12.2%) 74 (12.3%) Statin use: Asia/Pacific (0.89, (0.81, (0.46, 1.11) 1.31) 1.38) (10.0%) (8.6%) (13.0%) (9.9%) (8.9%) (10.7% 0.77 (0.62, 0.96) 192 (11.6%) 140 (8.9%) 0.94 (0.85, 1.04) 790 (10.3%) 747 (9.7% Renal dysfunction: (0.77, 0.99) (8.7%) 420 (7.6%) egfr: <60 ml/min/1.73m (0.89, (0.73, 1.19) 1.10) (14.2%) (17.0%) (14.5%) (15.2% 60 ml/min/1.73m 2 Hazard Ratio 0.96 (0.86, 1.07) 625 (9.2%) 604 (8.9% Polyvascular Disease: 0.93 (0.83, 1.04) (9.3%) 584 (8.7%) Baseline LDL: <70 mg/dl (0.78, (0.87, 1.17) 1.23) (16.3%) (8.7%) (15.6%) (9.0% 70 - <100 mg/dl 0.95 (0.81, 1.12) 291 (9.6%) 278 (9.1% Pre-Study CHD Event: 100 Recent mg/dl (0.72, (0.71, 1.08) 1.00) (10.2%) (13.7%) (9.1%) (11.6% Remote 0.96 (0.86, 1.07) 623 (10.4%) 596 (9.9%) hs C-reactive protein: <1.0 mg/l 1.00 (0.83, 1.22) (7.6%) 209 (7.6% Statin use: mg/l (0.46, (0.75, 1.38) 1.05) (13.0%) (10.8%) (10.7%) (9.7% >3.0 mg/l (0.85, (0.75, 1.04) 1.08) (10.3%) (13.6%) (9.7%) (12.2% egfr: Region: <60 ml/min/1.73m rth America 2 60 ml/min/1.73m Eastern Europe (0.73, (0.74, 1.10) 1.09) (17.0%) (10.6%) (15.2%) (9.5% (0.86, (0.77, 1.07) 1.15) (9.2%) (10.9%) (8.9%) (10.2%
19 Cardiovascular and Mortality Endpoints 19
20 Time to First Occurrence Major Coronary Events (CHD Death, MI, Urgent Coronary Revascularization) HR (95% CI)= 0.90 (0.82, 1.00) P-value = Placebo events = 814 Darapladib 160mg events =
21 Time to First Occurrence Total Coronary Events (CHD Death, MI, Any Coronary Revascularization, Hospitalization for Unstable Angina) HR (95% CI)= 0.91 (0.84, 0.98) P-value = Placebo events = 1269 Darapladib events =
22 Coronary-Specific Endpoints Component of pre-specified composite, but not a pre-specified endpoint 2 - Component of pre-specified composite, pre-specified as an endpoint of interest 22
23 Diarrhea/Odor Adverse Events Leading to Study Drug Discontinuation Placebo (N=7890) Darapladib (N=7912) n (%) Rate per 100 PY n (%) Rate per 100 PY Diarrhea 60 (0.8%) (3%) 0.92 Abnormal feces 5 (<0.1%) (2%) 0.64 Abnormal skin odor 4 (<0.1%) (2%) 0.63 Abnormal urine odor 1 (<0.1%) < (1%)
24 Adverse Events n (%) Placebo (N=7890) Rate per 100 PY n (%) Darapladib (N=7912) Anaphylaxis 7 (<0.1%) 9 (0.1%) 24 Rate per 100 PY Any serious adverse event 3448 (44%) (43%) Any adverse event leading to study drug discontinuation 1067 (14%) (20%) 6.25 Asthma 64 (0.8%) (0.5%) 0.15 Renal Effects Renal failure 89 (1.1%) (1.5%) 0.43 egfr (ml/min/1.73m 2 ): Mean (SD) change from baseline at end of treatment period 1.7 (14.4) -0.8 (14.1) Treatment difference (95% CI) -2.5 (-3.0, -2.1) Cancer New cancer 529 (6.7%) 508 (6.4%) Adjudicated new GI cancer 105 (1.3%) 102 (1.3%) Liver Events 52 (0.7%) 54 (0.7%)
25 Conclusions Darapladib in patients with stable CHD followed for 3.7 years on a background of optimal medical therapy Did not significantly reduce the incidence of the primary composite endpoint of CV death, MI or stroke There was no effect on stroke or total mortality Reduced the prespecified coronary-specific secondary endpoints of major coronary events (1% absolute) and total coronary events (1.5% absolute) with nominal significance (p<0.05) 25
26 Implications The STABILITY trial is the first large scale randomized global trial to test a novel mechanism of inhibition of inflammation in the atherosclerotic plaque Further analyses of the trial results in subgroups based on biomarkers, including Lp-PLA 2 levels, and genetics will explore if darapladib might be useful in specific patient subsets The STABILITY trial results indicate that darapladib warrants further evaluation in other clinical settings 26
27 Study Acknowledgements We would like to acknowledge all the study investigators, research staff and study patients, without whom this study would not be possible Sponsored by GlaxoSmithKline 27
GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
FOURIER STUDY GREYLOCK PRESS: CTS PRODUCT SAMPLE - FOURIER YES. Did the study achieve its main objective?
FOURIER STUDY Did the study achieve its main objective? 2 15% 1 5% 9.8% YES FOURIER compared Repatha with placebo in patients who were taking a statin and had hardening or narrowing of the arteries and
The Stabilization Of plaques using Darapladib (SOLID)-TIMI 52 trial: Primary Results
The Stabilization Of plaques using Darapladib (SOLID)-TIMI 52 trial: Primary Results Michelle L. O Donoghue MD MPH, on behalf of the SOLID-TIMI 52 investigators European Society of Cardiology Congress
Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin Marc S. Sabatine, MD, MPH on behalf of the PEGASUS-TIMI 54 Executive
Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB
Once-daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation Kenneth W. Mahaffey, MD and Keith AA Fox, MB ChB on behalf
The Stabilization Of plaques using. Primary Results
The Stabilization Of plaques using Darapladib (SOLID)-TIMI 52 trial: Primary Results Michelle L. O Donoghue MD MPH, on behalf of the SOLID-TIMI 52 investigators European Society of Cardiology Congress
Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière
Prevention of Cardiovascular events with Ivabradine: The SHIFT Study Saudi Arabia February 2011 Pr Michel KOMAJDA Université Pierre et Marie Curie Hospital Pitié Salpétrière Paris FRANCE Declaration Of
Expert Meeting on Large Simple Trials (LST s)
Expert Meeting on Large Simple Trials (LST s) Clinical Trials Transformation Initiative Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin JUPITER Johannes
New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
egfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 Year
CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study Results at 1 Year André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University
The TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
How would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People
November September 23, 20, 20102012 Heart Outcomes Prevention Evaluation (HOPE) - 3 Combined Lipid Lowering and Blood Pressure Lowering in Moderate Risk People Eva Lonn, Jackie Bosch, Jane Castelli, Andrea
Design and Analysis of a Cancer Prevention Trial: Plans and Results. Matthew Somerville 09 November 2009
Design and Analysis of a Cancer Prevention Trial: Plans and Results Matthew Somerville 09 November 2009 Overview Objective: Review the planned analyses for a large prostate cancer prevention study and
Beyond Framingham: Risk Assessment & Treatment for Primary Prevention
Beyond Framingham: Risk Assessment & Treatment for Primary Prevention Ronald M. Goldenberg, MD, FRCPC, FACE Consultant Endocrinologist, North York General Hospital Medical Co-Director, LMC Endocrinology
Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Martin Landray and Louise Bowman on behalf of the HPS 3 / TIMI 55 - REVEAL Collaborative
Review of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial
Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David
Summary of Results for Laypersons
What was the Study Called? Summary of Results for Laypersons A Randomized, Double-blind, Parallel-group, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability
Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC)
Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC) W. Schuyler Jones, MD FACC Director, Adult Cardiac Catheterization Laboratory
Long-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM
Long-term safety, tolerability and efficacy of alirocumab in high cardiovascular risk patients: ODYSSEY LONG TERM Efficacy by subgroup, and safety when LDL-C
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE
2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE Massimo F Piepoli, MD, PhD, FESC, Piacenza, Italy on behalf of the 6 th Joint Task Force 2 3 Guidelines still based upon the principles of
Protecting the heart and kidney: implications from the SHARP trial
Cardiology Update, Davos, 2013: Satellite Symposium Protecting the heart and kidney: implications from the SHARP trial Colin Baigent Professor of Epidemiology CTSU, University of Oxford S1 First CTT cycle:
Supplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
Methods. Background and Objectives STRADIVARIUS
STRADIVARIUS Effect of on Progression of Atherosclerosis in Patients with Abdominal Obesity and Coronary Artery Disease Steven E. Nissen MD Stephen J. Nicholls MBBS PhD, Kathy Wolski MPH, Josep Rodés-Cabau
Pharmacological Modification of Biomarkers and CV Risk
Pharmacological Modification of Biomarkers and CV Risk Jin-Ok Jeong Cardiovascular Center Chungnam National University Hospital Cardiovascular Center, Chungnam National University Hospital 1 The Ideal
Prof. Renata Cífková, MD, CSc.
Prof. Renata Cífková, MD, CSc. Head of the Department of Preventive Cardiology, Thomayer Teaching Hospital, Prague Focuses on arterial hypertension epidemiology, clinical trials, target organ damage prevention
Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH
Clinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
Experiences with interim trial monitoring, particularly with early stopped trials
Experiences with interim trial monitoring, particularly with early stopped trials 1 Robert J Glynn, ScD Divisions of Preventive Medicine and Pharmacoepidemiology & Pharmacoeconomics, Brigham & Women s
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION
Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION Dr Kornelia Kotseva National Heart & Lung Insitute Imperial College London, UK on behalf of all investigators participating
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University
surtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
The ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
Should I use statins?
I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of
An international, double-blind, phase III randomized trial. Main Results
An international, double-blind, phase III randomized trial Main Results Robert Hart on behalf of the NAVIGATE ESUS Steering Committee and Investigators Sponsorship & Disclosures NAVIGATE ESUS was sponsored
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4)
The Indian Polycap Study 1 & 2 (TIPS 1 & 2) and The International Polycap Study 3 & 4 (TIPS 3 & 4) Denis Xavier MD, MSc Professor and Head, Pharmacology, St. John's Medical College Coordinator, Division
Terms and Conditions. VISA Global Customer Assistance Services
Terms and Conditions VISA Global Customer Assistance Services Visa Global Customer Assistance Services (VGCAS) 1 The Visa Global Customer Assistance Services are co-ordinated by the Global Assistance Centre
Antihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
CHOLESTEROL-LOWERING THERAPHY
CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR
The PROSPECT Trial. A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively Identify Vulnerable Plaque
The PROSPECT Trial Providing Regional Observations to Study Predictors of Events in the Coronary Tree A Natural History Study of Atherosclerosis Using Multimodality Intracoronary Imaging to Prospectively
Landmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
Clinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
Disclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease
Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease Gjin Ndrepepa, Tomohisa Tada, Massimiliano Fusaro, Lamin King, Martin Hadamitzky,
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program Kenneth W. Mahaffey, Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Greg Fulcher,
After acute coronary syndromes patients continue to have recurrent ischemic events despite revascularization and dual antiplatelet therapy
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study
Felix Vallotton Ball (1899) LDL-C management in Asian diabetes: moderate vs. high intensity statin --- a lesson from EMPATHY study Conflict of interest disclosure None Committee of Scientific Affairs Committee
CVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
Five chapters 1. What is CVD prevention 2. Why is CVD prevention needed 3. Who needs CVD prevention 4. How is CVD prevention applied 5. Where should CVD prevention be offered Shorter, more adapted to clinical
Effective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
Imaging Biomarkers: utilisation for the purposes of registration. EMEA-EFPIA Workshop on Biomarkers 15 December 2006
Imaging Biomarkers: utilisation for the purposes of registration EMEA-EFPIA Workshop on Biomarkers 15 December 2006 Vascular Imaging Technologies Carotid Ultrasound-IMT IVUS-PAV QCA-% stenosis 2 ICH E
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
ACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club Announcements Next journal club Thursday, Dec. 14 th at 3:00 PM EST PACIFY Trial Effects of IV Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony C. Keech, Armando
Results of the GLAGOV Trial
Results of the GLAGOV Trial Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound Steven E. Nissen MD Stephen J. Nicholls MBBS PhD Consulting: Many companies
LLL Session - Nutrition support in diabetes and dyslipidemia. Dyslipidemia: targeting the management of cardiovascular risk factors. M.
ESPEN Congress Leipzig 2013 LLL Session - Nutrition support in diabetes and dyslipidemia Dyslipidemia: targeting the management of cardiovascular risk factors M. Leon Sanz (ES) Dyslipidemia: Targeting
Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
Heart Health Exploring the OTC options
Heart Health Exploring the OTC options (186 pages) Definitions & methodology Executive summary (26 pages) Overview Cardiovascular diseases are the world s biggest killer What are cardiovascular diseases?
Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound
Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound Department of Cardiovascular Medicine Heart and Vascular Institute
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS
GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS Table of Contents List of authors pag 2 Supplemental figure I pag 3 Supplemental figure II pag 4 Supplemental
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
Modelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford
Oxford Technology Showcase 2016 Big Healthcare Challenges in chronic disease Modelling diabetes Professor Alastair Gray Health Economics Research Centre University of Oxford Chronic diseases.. are long-term
The Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
PCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial
EBBINGHAUS: - A Cognitive Study of Patients Enrolled in the FOURIER Trial RP Giugliano, F Mach, K Zavitz, AC Keech, TR Pedersen, MS Sabatine, P Sever, C Kurtz, N Honarpour, BR Ott, on behalf of the EBBINGHAUS
The EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke
«L Europe de la santé au service des patients» 13-14 October 2008 - Institut Pasteur Paris Atherosclerotic Cardiovascular Diseases: ischaemic heart disease and stroke Simona Giampaoli National Centre of
New Insights into the Biology of Atherosclerosis and Primary Prevention: Controversy and Consensus in the JUPITER Trial
Fundacion Fernandez-CruzXXVIII Leccion Memorial New Insights into the Biology of Atherosclerosis and Primary Prevention: Controversy and Consensus in the JUPITER Trial Paul M Ridker, MD, MPH Eugene Braunwald
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
journal of medicine The new england Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Abstract
The new england journal of medicine established in 1812 november 20, 2008 vol. 359 no. 21 to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M Ridker, M.D., Eleanor Danielson,
Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD
Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD Cardiovascular Research Laboratories Research Institute of the McGill University Health Center Disclosure J.
DECLARATION OF CONFLICT OF INTEREST. Nothing to disclose
DECLARATION OF CONFLICT OF INTEREST Nothing to disclose Four-Year Clinical Outcomes of the OLIVUS (Impact of OLmesartan on progression of coronary atherosclerosis; evaluation by IntraVascular UltraSound
Global EHS Resource Center
Global EHS Resource Center Understand environmental and workplace safety requirements that affect your global operations. 800.372.1033 bna.com/gelw Global EHS Resource Center This comprehensive research
9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
Complications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
Identification of subjects at high risk for cardiovascular disease
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Identification of subjects at high risk for cardiovascular disease Lars Rydén Karolinska Institutet
4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
EU Market Situation for Poultry. Committee for the Common Organisation of the Agricultural Markets 20 April 2017
EU Market Situation for Poultry Committee for the Common Organisation of the Agricultural Markets 2 April 217 -9.% -11.% -5.% -.1% -.7% -2.2% 3.% 1.7% 1.2%.8%.6%.%.%.% 7.9% 7.% 6.4% 6.2% 6.% 5.5% 5.3%
Trial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
Ferrari R, Fox K, Bertrand M, Mourad J.J, Akkerhuis KM, Van Vark L, Boersma E.
Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular mortality in hypertension: a meta-analysis of randomized controlled trials Ferrari R, Fox K, Bertrand
Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL
TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL Otavio Berwanger, MD, PhD - On behalf of the TREAT Trial Steering
Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
Title for Paragraph Format Slide
Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38
Contemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
Data Alert. Vascular Biology Working Group. Blunting the atherosclerotic process in patients with coronary artery disease.
1994--4 Vascular Biology Working Group www.vbwg.org c/o Medical Education Consultants, LLC 25 Sylvan Road South, Westport, CT 688 Chairman: Carl J. Pepine, MD Eminent Scholar American Heart Association